Go Pro
→ A valet parking cars made $37,212 in one weekend (From Tim Sykes) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$865.04
-1.2%		$879.13
$631.47
▼
$953.58
$54.76B0.46286,445 shs250,017 shs
Natera, Inc. stock logo
NTRA
Natera
$322.10
+21.4%		$254.03
$149.38
▼
$323.01
$38.01B1.511.07 million shs3.39 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$784.36
+1.6%		$657.28
$541.00
▼
$821.11
$81.63B0.22781,724 shs837,569 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$496.07
+2.5%		$474.84
$362.50
▼
$533.67
$122.85B0.31.34 million shs992,438 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-1.17%+1.31%-5.49%+10.59%+28.51%
Natera, Inc. stock logo
NTRA
Natera
+21.37%+20.29%+17.39%+65.83%+133.19%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.59%+2.85%+18.33%+9.72%+41.29%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+2.49%+3.98%-0.47%+15.41%+28.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$865.04
-1.2%		$879.13
$631.47
▼
$953.58
$54.76B0.46286,445 shs250,017 shs
Natera, Inc. stock logo
NTRA
Natera
$322.10
+21.4%		$254.03
$149.38
▼
$323.01
$38.01B1.511.07 million shs3.39 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$784.36
+1.6%		$657.28
$541.00
▼
$821.11
$81.63B0.22781,724 shs837,569 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$496.07
+2.5%		$474.84
$362.50
▼
$533.67
$122.85B0.31.34 million shs992,438 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-1.17%+1.31%-5.49%+10.59%+28.51%
Natera, Inc. stock logo
NTRA
Natera
+21.37%+20.29%+17.39%+65.83%+133.19%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.59%+2.85%+18.33%+9.72%+41.29%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+2.49%+3.98%-0.47%+15.41%+28.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.92
Moderate Buy$1,056.8922.18% Upside
Natera, Inc. stock logo
NTRA
Natera
2.77
Moderate Buy$299.65-6.97% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.67
Moderate Buy$797.751.71% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.92
Moderate Buy$563.5013.59% Upside

Current Analyst Ratings Breakdown

Latest NTRA, VRTX, REGN, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $340.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$275.00 ➝ $350.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$348.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$375.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$220.00 ➝ $284.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$300.00 ➝ $315.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $320.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$330.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$340.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$315.00 ➝ $360.00
8/5/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B12.74$21.08 per share41.03$134.54 per share6.43
Natera, Inc. stock logo
NTRA
Natera
$2.31B20.00N/AN/A$12.38 per share26.02
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.78$42.65 per share18.39$299.96 per share2.61
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B10.49$18.01 per share27.54$79.78 per share6.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0433.2224.181.1132.19%43.59%36.66%N/A
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.63N/AN/AN/A-7.11%-11.82%-8.19%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4619.3915.521.3227.86%13.47%10.34%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1828.8726.792.0035.00%23.09%16.72%N/A

Latest NTRA, VRTX, REGN, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.48%N/A9.29%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest NTRA, VRTX, REGN, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.51%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Natera, Inc. stock logo
NTRA
Natera
N/A
2.96
2.83
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.57

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140143.21 million135.98 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410105.72 million98.35 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Beacon Investment Advisory Services Inc.
August 8 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-beacon-investment-advisory-services-inc-2026-08-08/
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB)
August 7 at 11:39 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX-Q/pressreleases/3700111/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-and-q32-bio-qttb/
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)
August 7 at 11:39 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX-Q/pressreleases/3708949/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-ocular-therapeutix-ocul-and-arcus-biosciences-rcus/
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
August 7 at 6:39 PM  |  fool.comhttps://www.fool.com/investing/2026/08/07/could-1-tiny-biotech-topple-vertex-pharmaceuticals/
What Insmed Stock's Premium Is Actually Buying
August 7 at 1:39 PM  |  trefis.comT
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Czech National Bank
August 7 at 6:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-purchased-by-czech-national-bank-2026-08-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by PensionDanmark Pensionsforsikringsaktieselskab
August 7 at 6:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-acquired-by-pensiondanmark-pensionsforsikringsaktieselskab-2026-08-07/
Assenagon Asset Management S.A. Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
August 7 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-increases-stock-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-07/
IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises
August 7 at 3:37 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ionq-q2-earnings-miss-estimates-143900622.html
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
August 6 at 12:35 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3685001/barclays-sticks-to-its-buy-rating-for-vertex-pharmaceuticals-vrtx/
Vertex Pharmaceuticals (VRTX) Gets a Buy from Scotiabank
August 6 at 12:35 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3665074/vertex-pharmaceuticals-vrtx-gets-a-buy-from-scotiabank/
Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project
August 6 at 12:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/energy/articles/vortex-energy-receives-final-technical-120000170.html
Cantor Fitzgerald Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $595.00
August 6 at 2:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943678
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
August 6 at 2:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943681
AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...
August 6 at 2:34 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/abcellera-biologics-inc-abcl-q2-050141623.html
Can Vertex Pharmaceuticals (NASDAQ:VRTX) Carry Its Momentum Into New Therapies?
August 5 at 4:33 PM  |  kalkinemedia.comK
Vertex Pharmaceuticals (NASDAQ:VRTX) In Focus As Earnings Meet Franchise Expansion
August 5 at 6:32 AM  |  kalkinemedia.comK
Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-seen-well-positioned-170515212.html
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
August 4, 2026  |  fool.comhttps://www.fool.com/investing/2026/08/04/why-vertex-pharmaceuticals-stock-ticked-higher-on/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=5de63096-502f-4ac8-9f45-bb7a3d7bb658
Vertex’s biggest overhang: a rival 50 times smaller
August 4, 2026  |  biopharmadive.comB
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vrtx-q2-earnings-call-highlights-140000292.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Illuminated AV logo displayed on a riveted metal panel surrounded by cables and machinery components.
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
By Jeffrey Neal Johnson | July 10, 2026
Fighter jet fuselage with cockpit in a hangar displaying the Lockheed Martin logo.
Lockheed Martin Secures the Ultimate Defense Moat
By Jeffrey Neal Johnson | July 9, 2026
Steam rises from a power plant cooling tower silhouetted against a glowing sunset sky.
3 Energy Stocks Racing to Fix AI's Power Problem
By Bridget Bennett | July 14, 2026
Aerial view of a water treatment plant with circular clarifiers, pipelines, and a reservoir behind it.
These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending
By Nathan Reiff | July 14, 2026
argenex stock logo

argenex NASDAQ:ARGX

$865.04 -10.26 (-1.17%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$864.86 -0.18 (-0.02%)
As of 08/7/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Natera stock logo

Natera NASDAQ:NTRA

$322.10 +56.72 (+21.37%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$320.92 -1.18 (-0.36%)
As of 08/7/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$784.36 +12.25 (+1.59%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$777.31 -7.05 (-0.90%)
As of 08/7/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$496.07 +12.04 (+2.49%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$496.00 -0.07 (-0.01%)
As of 08/7/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas